Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.

Journal for immunotherapy of cancer - 1 May 2021

Park Jeong A, Santich Brian H, Xu Hong, Lum Lawrence G, Cheung Nai-Kong V

Abstract excerpt

BACKGROUND: T cell-based immunotherapies using chimeric antigen receptors (CAR) or bispecific antibodies (BsAb) have produced impressive responses in hematological malignancies. However, major hurdles remained, including cytokine release syndrome, neurotoxicity, on-target off-tumor effects, reliance on autologous T cells, and failure in most solid tumors. BsAb armed T cells offer a safe alternative. METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Coculture Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Immunotherapy, Adoptive

Share to Lymphocyte Activation

Share to Lymphocytes, Tumor-Infiltrating

Share to Tumor Microenvironment

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33986124
DOI: 10.1136/jitc-2020-002222
PMCID: PMC8126293

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.PMID 33986124Read ↗

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.Semantic proximity Read ↗

In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiformeSemantic proximity Read ↗

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagersSemantic proximity Read ↗

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine LoopSemantic proximity Read ↗

A Simplified Function-First Method for the Discovery and Optimization of Bispecific Immune Engaging AntibodiesSemantic proximity Read ↗

Engineered NKG2C <sup>+</sup> NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndromeSemantic proximity Read ↗

CAR-T-Cell Therapy: Present Progress and Future strategiesSemantic proximity Read ↗

Four challenges to CAR T cells breaking the glass ceilingSemantic proximity Read ↗

Universal Dual-Target CAR-γδT Cells Targeting B7-H3 and IL13Rα2 for Glioblastoma TherapySemantic proximity Read ↗

Novel Approaches to Enhance the Specificity and Safety of Engineered T CellsSemantic proximity Read ↗

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.Semantic proximity Read ↗

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.